INDICATIONS
Because needle core biopsy of the liver is associated with a small but definite risk, biopsy should only be performed when the findings assist in the management of the patient. With this stated, the following are generally accepted indications for percutaneous liver biopsy (1) . · Elevated liver enzyme levels with no explanation (ie, rising enzyme profile or initial marked enzyme elevation) · Elevated aminotransferase levels for six months or longer · Hepatomegaly of unclear etiology · Assessment of response to therapy of chronic liver disease · Unexplained jaundice without evidence of extrahepatic obstruction · Monitoring of hepatotoxicity of drug therapy · Fever of unknown origin · Liver transplant evaluation
The prebiopsy work-up of a patient requiring liver biopsy should include informed consent, including an explanation of the risks of the procedure and the following laboratory tests obtained within one week before biopsy. · Prothrombin time-international normalized ratio and partial thromboplastin time. · Platelet count · Hemoglobin · Blood urea nitrogen and creatinine · Group and screen · Bleeding time if acetylsalicylic acid (ASA)/nonsteroidal anti-inflammatory drug (NSAID) status is uncertain
Patients should be advised to avoid ASA and NSAIDs for one week before biopsy. Anticoagulants should be stopped for any liver biopsy.
The route of biopsy should be governed by the clinical situation. Percutaneous liver biopsy by experienced personnel is most often done. Use of ultrasound or computerized tomography to guide biopsies, although frequently used, has Postbiopsy management should include a recording by the physician performing the biopsy of how many 'passes' were made, any medications administered and any apparent complications. Suggested postbiopsy orders are that the patient have complete bed rest for a minimum of 2 h, and that vital signs, including blood pressure, pulse and respiration, be obtained every 15 mins for 1 h and then at regular intervals until discharge.
Same day discharge is the norm in many centres, although it should be recognized there is a small admission rate to hospital for complications. Patients should be discharged with follow-up instructions and should be instructed to avoid NSAIDs, ASA, warfarin, ticlid and any other anticoagulants for one week.
CONTRAINDICATIONS

Contraindications to percutaneous liver biopsy include (1)
· an uncooperative patient; · impaired coagulation; · severe uncorrected anemia; · significant ascites; · infection in the path of the needle; · suspected extrahepatic biliary obstruction of high grade; · cholangitis; · echinococcal cysts; · no safe unobstructed access route to biopsy; · leukemia and myelofibrosis; and · uremia.
COMPLICATIONS
Complications may be divided into minor complications and major complications. Minor complications include pain and transient hypotension (3.5% to 33% if pain included). Major complications include significant hypotension, pneumothorax, hemothorax, hemoperitoneum, hemobilia, significant intrahepatic hematoma, cardiac arrhythmia, gallbladder perforation and biopsy of other organs such as kidney or pancreas (2) .
The most significant complication of liver biopsy is death, with reports ranging from 0% to 0.33% in the literature.
CONCLUSION
Liver biopsy remains an essential investigation for the diagnosis of liver disease. With strict attention to indications and contraindications, liver biopsy can be regarded as a safe and useful procedure.
